Larazotide: the peptide studied for leaky gut, explained

A small synthetic peptide has been at the center of intestinal-barrier research for two decades. Here is what scientists have learned.

TL;DR

• Larazotide (also called larazotide acetate or AT-1001) is a synthetic eight-amino-acid peptide studied for its ability to regulate tight junctions — the seals between gut-lining cells.
• Researchers have studied it most extensively in celiac disease (in plain English: an autoimmune condition triggered by gluten), where intestinal-barrier disruption is a key feature.
• Larazotide is not FDA-approved and is not a marketed drug. It remains investigational as of 2026.

What is larazotide

Larazotide — formally larazotide acetate, also known in early research as AT-1001 — is a synthetic peptide (in plain English: a short chain of amino acids made in a lab). It was developed by Alba Therapeutics and consists of eight amino acids. Its target is the intestinal tight junction. That is the microscopic molecular seal that holds adjacent cells of the gut lining together and controls what passes into the bloodstream. When tight junctions open more than they should, the condition is sometimes called "leaky gut," or more precisely increased intestinal permeability.

How does larazotide work

Think of the gut lining as a brick wall, and tight junctions as the mortar between the bricks. When the mortar weakens, gaps open. Larazotide is thought to act as a zonulin antagonist — it may block zonulin (a signaling protein that loosens tight junctions) from opening those gaps. In laboratory and early clinical studies, it has also been linked to rearrangement of the proteins that form tight junction complexes. Think of it as helping the mortar set back in place. This mechanism is distinct from treatments that address the underlying immune trigger. Larazotide targets the structural barrier itself.

Who asks about it

People come to this topic most often through two paths. The first is a celiac disease diagnosis. Patients who follow a strict gluten-free diet (GFD) but still have gastrointestinal symptoms often want to know what adjunct options their physician might consider. The second path is broader interest in gut-barrier science. These are readers who have encountered the term "leaky gut" and want to understand what compounds researchers are actually studying.

What the research says

The most rigorous human data on larazotide comes from a multicenter, randomized, double-blind, placebo-controlled trial in 342 adults with celiac disease published in Gastroenterology. Participants on a GFD received either larazotide acetate (at 0.5 mg, 1 mg, or 2 mg three times daily) or placebo for 12 weeks. The 0.5 mg dose met the primary endpoint: patients reported a 26% decrease in symptomatic days and a 31% increase in improved-symptom days versus placebo (Leffler et al., Gastroenterology, 2015). An earlier randomized trial tested larazotide during a deliberate gluten challenge. It found reduced intestinal permeability and fewer gastrointestinal symptoms in the larazotide group (Kelly et al., Gut, 2013). These are findings from specific trial populations, not the basis for any currently approved treatment.

What to know before considering it

Larazotide is not FDA-approved. It is not available as a compounded prescription peptide. It has been studied in clinical trials for celiac disease specifically. It is not indicated for general "leaky gut," irritable bowel syndrome, or other gastrointestinal conditions outside of a research setting. The evidence base is promising but limited in size and scope. No compound that acts on tight junctions has received regulatory approval for intestinal-permeability indications as of 2026. Any clinical interest in investigational gut-barrier compounds requires evaluation and guidance from a licensed clinician.

The Halftime POV

Gut-barrier science is one of the more genuinely interesting frontiers in medicine. The research on tight junctions and intestinal permeability is rigorous, peer-reviewed, and ongoing — and larazotide has played a real role in that story. At Halftime Health, we follow this research because understanding how the body's barriers work matters for the second half. It is part of the larger picture of how to maintain health over time. This is the kind of science worth knowing about, even when the compounds themselves are not yet in clinical use.

Related reading:

• What is a peptide? A plain-English primer
• How peptides bind to receptors: a plain-English guide
• Peptide risks: what to know before you start
• Peptide regulatory landscape 2026

---

FAQ

Q: What is larazotide? A: Larazotide — also called larazotide acetate or AT-1001 — is a synthetic eight-amino-acid peptide. It was developed to act on tight junctions, the microscopic seals between cells that line the intestinal wall. It is investigational: it is not FDA-approved and is not currently available as a marketed drug.

Q: How does larazotide work? A: Larazotide is studied as a zonulin antagonist (in plain English: a compound that may block a signaling protein called zonulin that loosens the seals between gut cells). By acting on tight junctions, it is thought to help limit the increase in intestinal permeability associated with conditions like celiac disease. It targets the structural barrier of the gut, not the immune response directly.

Q: Is larazotide FDA approved? A: No. As of 2026, larazotide is not FDA-approved. It has been studied in Phase II clinical trials for celiac disease, including a randomized controlled trial published in Gastroenterology in 2015. It is not available as a compounded or commercially prescribed peptide.

Q: What is the difference between larazotide and a gluten-free diet for celiac disease? A: A gluten-free diet (GFD) removes the immune trigger — gluten — from the equation. Larazotide, in contrast, targets the intestinal barrier directly. In clinical trials, it was studied as an add-on to an existing GFD, not as a replacement for one. It addresses a different part of the disease process.

---

Disclaimer

This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.

Get updates

Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.

---

Sources

• Leffler DA et al., "Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial," Gastroenterology (2015)
• Kelly CP et al., "Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study," Gut (2013)

---